Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials (Q37059366)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 May 2016

Language	Label	Description	Also known as
English	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials	scientific article published on 23 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

object named as

John B Buse

2

0 references

Ralph A. DeFronzo

1

object named as

Ralph A DeFronzo

1 reference

Europe PubMed Central

18 August 2017

5

object named as

Sharon Skare

1 reference

Europe PubMed Central

18 August 2017

author name string

Terri Kim

3

1 reference

Europe PubMed Central

18 August 2017

Colleen Burns

4

1 reference

Europe PubMed Central

18 August 2017

Alain Baron

6

1 reference

Europe PubMed Central

18 August 2017

Mark Fineman

7

1 reference

Europe PubMed Central

18 August 2017

publication date

23 May 2016

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

59

1 reference

Europe PubMed Central

18 August 2017

1645-1654

1 reference

Europe PubMed Central

18 August 2017

8

1 reference

Europe PubMed Central

18 August 2017

copyright license

Creative Commons Attribution 4.0 International

23 May 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s00125-016-3992-6

0 references

Metformin and the gastrointestinal tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Metformin-associated lactic acidosis: Current perspectives on causes and risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Metformin--mode of action and clinical implications for diabetes and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Clinical Pharmacokinetics of Metformin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Incidence of lactic acidosis in metformin users

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Metformin kinetics in healthy subjects and in patients with diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

29 September 2017

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

27 June 2018

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

27 June 2018

Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

27 June 2018

Metformin in the digestive tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

27 June 2018

Pharmacokinetics of metformin after intravenous and oral administration to man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

27 June 2018

[11C]-Labeled Metformin Distribution in the Liver and Small Intestine Using Dynamic Positron Emission Tomography in Mice Demonstrates Tissue-Specific Transporter Dependency.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Metformin and the intestine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Mechanisms underlying saturable intestinal absorption of metformin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Differential effects of metformin on bile salt absorption from the jejunum and ileum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4930485

4 September 2018

Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3992-6

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3992-6

21 January 2018

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3992-6

21 January 2018

Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-016-3992-6

21 January 2018

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Aspects of sleep effects on the digestive tract]

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accumulation of metformin by tissues of the normal and diabetic mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comment on 'A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure'

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27216492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-016-3992-6

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37059366&oldid=2119334194"